MX2014009751A - Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. - Google Patents

Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.

Info

Publication number
MX2014009751A
MX2014009751A MX2014009751A MX2014009751A MX2014009751A MX 2014009751 A MX2014009751 A MX 2014009751A MX 2014009751 A MX2014009751 A MX 2014009751A MX 2014009751 A MX2014009751 A MX 2014009751A MX 2014009751 A MX2014009751 A MX 2014009751A
Authority
MX
Mexico
Prior art keywords
antibodies
integrin
avvb6
same
treat cancer
Prior art date
Application number
MX2014009751A
Other languages
English (en)
Other versions
MX360141B (es
Inventor
Maureen Ryan
Django Sussman
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2014009751A publication Critical patent/MX2014009751A/es
Publication of MX360141B publication Critical patent/MX360141B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona anticuerpos que se unen específicamente a integrina avß6. Los anticuerpos son útiles para el tratamiento y el diagnóstico de diversos tipos de cáncer, así como la detección de avß6.
MX2014009751A 2012-02-17 2013-02-14 Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. MX360141B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600499P 2012-02-17 2012-02-17
US201261602511P 2012-02-23 2012-02-23
PCT/US2013/026087 WO2013123152A2 (en) 2012-02-17 2013-02-14 ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER

Publications (2)

Publication Number Publication Date
MX2014009751A true MX2014009751A (es) 2015-02-24
MX360141B MX360141B (es) 2018-10-24

Family

ID=48984888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009751A MX360141B (es) 2012-02-17 2013-02-14 Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.

Country Status (14)

Country Link
US (5) US9493566B2 (es)
EP (1) EP2814509B1 (es)
JP (1) JP6273214B2 (es)
KR (1) KR102084806B1 (es)
CN (2) CN104220094A (es)
AU (1) AU2013221585B2 (es)
BR (1) BR112014019861A2 (es)
CA (1) CA2862319C (es)
EA (1) EA031069B1 (es)
HK (1) HK1211035A1 (es)
IL (1) IL233742B (es)
MX (1) MX360141B (es)
SG (1) SG11201404354UA (es)
WO (1) WO2013123152A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294178B1 (en) 2008-05-23 2014-07-16 Siwa Corporation Methods for facilitating regeneration
JP6527508B2 (ja) * 2013-10-01 2019-06-05 メディミューン リミテッド αＶβ６を過剰発現する癌を治療及び診断する方法
NZ717668A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
CN106029083B (zh) 2014-02-17 2020-02-07 西雅图基因公司 亲水性抗体-药物偶联物
WO2015164627A1 (en) * 2014-04-23 2015-10-29 Discovery Genomics, Inc. Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP4067386A1 (en) 2016-02-19 2022-10-05 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
WO2018191718A1 (en) * 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
CA3017527A1 (en) 2016-03-25 2017-09-28 Seattle Genetics, Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
CN109562152B (zh) 2016-08-09 2024-04-02 西雅图基因公司 含有具有改善的生理化学性质的自稳定性接头的药物缀合物
EA201990890A1 (ru) 2016-10-18 2019-10-31 Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
JP7291624B2 (ja) * 2016-11-01 2023-06-15 アローヘッド ファーマシューティカルズ インコーポレイテッド アルファ－ｖベータ－６インテグリンリガンド及びその使用
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
KR20190141181A (ko) 2017-04-27 2019-12-23 시애틀 지네틱스, 인크. 사차화된 니코틴아미드 아데닌 다이뉴클레오타이드 구제 경로 억제제 콘쥬게이트
AU2018359515A1 (en) * 2017-11-01 2020-06-18 Arrowhead Pharmaceuticals, Inc. Integrin ligands and uses thereof
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
AU2019225845A1 (en) 2018-02-20 2020-09-24 Seagen Inc. Hydrophobic Auristatin F compounds and conjugates thereof
CN114828887A (zh) * 2019-12-05 2022-07-29 思进公司 抗-αVβ6抗体和抗体-药物偶联物
CA3164037A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CA3176248A1 (en) 2020-04-10 2021-10-14 Seagen Inc. Charge variant linkers
EP4326333A1 (en) 2021-04-20 2024-02-28 Seagen Inc. Modulation of antibody-dependent cellular cytotoxicity
WO2022251850A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
NZ515955A (en) 1997-08-08 2003-04-29 Univ California Hybridoma producing a monoclonal antibody against beta-6 integrin
EP2165714B1 (en) * 2001-04-30 2013-10-23 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
ME00804B (me) 2002-03-13 2012-03-20 Biogen Idec Inc Anti-alpha v beta 6 antitela
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US20040048312A1 (en) 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
US7241598B2 (en) * 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
CA2582157A1 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
KR101281501B1 (ko) * 2004-12-09 2013-07-15 얀센 바이오테크 인코포레이티드 항인테그린 면역 컨쥬게이트, 방법 및 용도
ES2429340T3 (es) * 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
AU2006286498A1 (en) 2005-08-31 2007-03-08 Novo Nordisk Health Care Ag Human FVII monoclonal antibodies binding the GLA domain and use thereof
AU2007348941B2 (en) 2006-08-03 2011-08-04 Medimmune Limited Antibodies directed to alphaVbeta6 and uses thereof
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CA2665885A1 (en) 2006-10-19 2008-12-04 The Regents Of The University Of California Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6
RU2010133547A (ru) * 2008-01-11 2012-02-20 Дзе Юниверсити Оф Токио (Jp) Анти-cldn антитела
EP2245066A2 (en) * 2008-01-22 2010-11-03 Biogen Idec MA Inc. Ron antibodies and uses thereof
WO2009119258A1 (ja) 2008-03-27 2009-10-01 テルモ株式会社 生体吸収性材料およびそれを用いた生体内留置物
AU2009245724A1 (en) 2008-05-09 2009-11-12 Ablynx N.V. Amino acid sequences directed against integrins and uses thereof
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
KR101138460B1 (ko) 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
AU2011329647B2 (en) 2010-11-19 2015-10-22 Eisai R&D Management Co., Ltd. Neutralizing anti-CCL20 antibodies
ES2875535T3 (es) 2012-03-29 2021-11-10 Biogen Ma Inc Biomarcadores para su uso en aplicaciones de terapia de integrina

Also Published As

Publication number Publication date
BR112014019861A2 (pt) 2017-07-04
IL233742A0 (en) 2014-09-30
EA031069B1 (ru) 2018-11-30
AU2013221585A1 (en) 2014-08-14
JP6273214B2 (ja) 2018-01-31
CA2862319A1 (en) 2013-08-22
EP2814509A4 (en) 2015-12-09
MX360141B (es) 2018-10-24
CA2862319C (en) 2021-11-30
EP2814509A2 (en) 2014-12-24
EA201491541A1 (ru) 2016-05-31
EP2814509B1 (en) 2018-05-16
CN104220094A (zh) 2014-12-17
AU2013221585B2 (en) 2017-03-30
US20230242648A1 (en) 2023-08-03
JP2015509938A (ja) 2015-04-02
WO2013123152A2 (en) 2013-08-22
SG11201404354UA (en) 2014-10-30
WO2013123152A3 (en) 2014-11-13
US9493566B2 (en) 2016-11-15
CN105017420B (zh) 2019-05-28
IL233742B (en) 2019-08-29
US20210340260A1 (en) 2021-11-04
US20160376368A1 (en) 2016-12-29
US20200031938A1 (en) 2020-01-30
US20160009806A1 (en) 2016-01-14
CN105017420A (zh) 2015-11-04
HK1211035A1 (en) 2016-05-13
KR102084806B1 (ko) 2020-03-04
KR20140127875A (ko) 2014-11-04

Similar Documents

Publication Publication Date Title
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
TN2015000396A1 (en) Antibody drug conjugates
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
SG10201704992SA (en) Lsr antibodies, and uses thereof for treatment of cancer
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX2013013226A (es) Anticuerpos c-kit y usos de los mismos.
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
EA201400178A1 (ru) Лечение рака молочной железы
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
IN2014DN09717A (es)
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
MX362497B (es) Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
GB201212690D0 (en) Materials and methods for treating pten mutated or deficient cancer
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.
IL232340A0 (en) lsr antibodies, and their uses for cancer treatment

Legal Events

Date Code Title Description
FG Grant or registration